Natalizumab for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients- 5-Year Budget Impact Analysis (BIA) from the Brazilian Public Payer Perspective
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.1814
https://www.valueinhealthjournal.com/article/S1098-3015(13)03719-4/fulltext
Title :
Natalizumab for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients- 5-Year Budget Impact Analysis (BIA) from the Brazilian Public Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)03719-4&doi=10.1016/j.jval.2013.08.1814
First page :
A621
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1658